PhaseBio Pharmaceuticals, Inc. (PHAS)
Stock Price:
$3.66 USD
0.22 (6.40%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
107.40M |
| Revenue (ttm) |
1.33M |
| Net Income (ttm) |
-65.77M |
| Shares Out |
29.34M |
| EPS (ttm) |
-2.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$3.66 |
| Previous Close |
$3.44 |
| Change ($) |
0.22 |
| Change (%) |
6.40% |
| Day's Open |
3.49 |
| Day's Range |
3.45 - 3.70 |
| Day's Volume |
200,402 |
| 52-Week Range |
2.60 - 8.49 |
More Stats
| Market Cap |
107.40M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.34M |
| Float |
15.40M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-2.29 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.83M |
| Short Ratio |
16.84 |
| Short % of Float |
24.85% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
81.05 |
| PB Ratio |
3.82 |
| Revenue |
1.33M |
| Operating Income |
n/a |
| Net Income |
-65.77M |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
n/a |
| Gross Margin |
-2,154.72% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-45.51% |
| ROE |
-121.79% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.73*
(193.17% upside)
Low
3.91
Current: $3.66
High
18.00
Target: 10.73
*Average 12-month price target from 4 stock analysts.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
PhaseBio Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
50 |
| CEO |
Jonathan P. Mow |
Stock Information
| Ticker Symbol |
PHAS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PHAS |
| IPO Date |
October 18, 2018 |
Description
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.